Skip to content

Determination of the half effective dose of ciprofol in the diagnosis and treatment of gastrointestinal endoscopy to inhibit the reaction of endoscopic insertion

Determination of the half effective dose of ciprofol combined with sufentanil for inhibiting the reaction of endoscopic insertion in the diagnosis and treatment of gastrointestinal endoscopy by sequential method

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056608
Enrollment
Unknown
Registered
2022-02-09
Start date
2022-02-07
Completion date
Unknown
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endoscope insertion reaction

Interventions

Adult group:Ciprofol
elderly group:Ciprofol

Sponsors

Affiliated Hospital of Guizhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients undergoing upper gastrointestinal endoscopy under intravenous anesthesia; 2. American Society of Anesthesiologists (ASA) anesthesia class I or II; 3. Gender is not limited. Adult group: age >=18 and =65 years old. 4. Body mass index (BMI) >= 18 and <= 30kg/m2; 5. Those who can understand the experimental protocol and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those with contraindications to deep sedation/anesthesia, or those who have experienced sedation/anesthesia accidents in the past; 2. Those who are known to be allergic to eggs, soy products, opioids and their hangover drugs, propofol, etc.; 3. Pathological obesity/obstructive sleep apnea; 4. Acute upper respiratory tract infection or asthma attack within 1 week; 5. Uncontrolled severe hypertension; 6. Severe liver and kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
Endoscope insertion reaction;

Secondary

MeasureTime frame
Vital signs change;

Countries

China

Contacts

Public ContactXiaohua Zou

Affiliated Hospital of Guizhou Medical University

562931613@qq.com+86 13809416036

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026